Corporate Overview

December 2020 Passionately pursuing a better life for patients with cancer Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Actual results or events could differ materially from the plans, intentions and Private Securities Litigation Reform Act of 1995 that involve substantial risks and expectations disclosed in the forward-looking statements AVEO makes due to a uncertainties. All statements, other than statements of historical facts, contained in this number of important factors, including substantial risks and uncertainties relating to: presentation are forward-looking statements. The words “anticipate,” “believe,” AVEO’s ability, and the ability of its licensees, to demonstrate to the satisfaction of “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” applicable regulatory agencies such as the FDA and the EMA the safety, efficacy and “will,” “would,” “could,” “should,” “continue,” “contemplate,” “seek,” “look forward,” clinically meaningful benefit of AVEO’s product candidates, including, in particular, “advance,” “goal,” “strategy,” “promising,” “opportunity” or the negative of these terms tivozanib; AVEO’s and its collaborators’ ability to successfully enroll and complete or other similar expressions are intended to identify forward-looking statements, clinical trials; the impacts of the COVID-19 pandemic on AVEO’s clinical trials, although not all forward-looking statements contain these identifying words. These business and operations; AVEO’s ability to enter into and maintain its third party forward-looking statements include, among others, statements about: AVEO’s goals collaboration and license agreements, and its ability, and the ability of its strategic and business strategy, prospects, plans and objectives; AVEO’s plans regarding partners, to achieve development and commercialization objectives under these communications with the U.S. Food and Drug Administration (FDA) for tivozanib; the arrangements; the timing and costs of seeking and obtaining regulatory approval; timing, design and results of preclinical and clinical trials; the timing and outcome of AVEO’s ability to maintain compliance with regulatory requirements applicable to its meetings with and applications to regulatory authorities by AVEO and its partners, product candidates; AVEO’s ability to obtain and maintain adequate protection for including AVEO’s marketing application filed with the FDA for tivozanib; the intellectual property rights relating to its product candidates; AVEO’s ability to competitive landscape for, and the potential utility of, AVEO’s product candidates, successfully implement its strategic plans, including its ability to successfully launch AVEO’s statements regarding the potential efficacy, safety and tolerability profile of and commercialize tivozanib if it is approved by the FDA; AVEO’s ability to raise the tivozanib and ; the potential commercial opportunity of tivozanib and substantial additional funds required to achieve its goals, including those goals AVEO’s other product candidates and AVEO’s estimates for its cash runway and the pertaining to the development and commercialization of tivozanib; unplanned capital contingencies on which such runway is dependent. requirements; AVEO’s ability to access up to $20.0 million of the Hercules loan facility, which turns on the achievement of milestones related to the approval and commercialization of tivozanib in the U.S., which milestones may not be achieved; adverse general economic and industry conditions; and those risks discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s quarterly and annual reports on file with the SEC and in other filings that AVEO may make with the SEC in the future. All forward-looking statements contained in this presentation speak only as of the date of this presentation, and AVEO undertakes no obligation, and specifically disclaims any obligation, to update any of these statements, except as required by law. 2 AVEO Oncology: Investment Thesis

Multiple late-stage oncology assets, promising early-stage pipeline, cash & runway into 2022* enable strategy for consistent long-term growth

Tivozanib: Tivozanib: Ficlatuzumab: Early-stage Pipeline Monotherapy R/R CPI Combos HNSCC, AML, for Significant RCC & (RCC, HCC, other) Pancreatic Unmet Needs

• TIVO-3: • Selectivity and T-reg • Growing body of clinical data • IND planned for • First positive pivotal trial in downregulation enable supports potential to address AV-380 in 2020 in large third+ line RCC unique combination significant unmet need in indication (cancer cachexia) multiple indications • First randomized study stratifying for prior CPI • Clinical collaborations with • Retained interest in population leading CPI companies • Initiating clinical manufacture to potentially high-value enable a potential registrational program: KHK4951 (tivozanib Phase 3 trial in HNSCC reformulation) for wet age- • Potential to expand a large, related macular degeneration unaddressed market in R/R (AMD) being developed by RCC Kyowa Kirin

• NDA filing accepted for R/R RCC • March 31, 2021 PDUFA date

3 CPI – checkpoint inhibitor *See slide 34 Multiple Potential Opportunities for Value Creation

Regulatory Clinical Preclinical Phase 1 Phase 2 Phase 3 Filing Marketed Partner Tivozanib (RCC) TIVO-1 Ex-US (Phase 3 Registration Study in 1st Line RCC) VEGFR TKI (Europe)

TIVO-3 (Phase 3 Registration Study in 3rd Line RCC)

TiNivo (+OPDIVO® RCC)

Tivozanib (HCC) (1st line HCC+ IMFINZI®) VEGFR TKI DEDUCTIVE Ficlatuzumab (Ficla +/- ERBITUX®) Anti-HGF/c-MET HNSCC mAb Pancreatic (Ficla + Nab-paclitaxel + Gemcitabine)

CyFi-1 (AML HiDac +/- Ficla)

AV-203 (CAN017) Oncology Anti-ERBB3 mAb

Pre-Clinical AV-380 Anti-GDF15 mAb Cachexia

AV-353 Anti-Notch 3 mAb Oncology

4 Tivozanib Unique combination of anti-tumor activity and tolerability Tivozanib: A Differentiated VEGFR 1, 2 and 3 TKI Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities

Tivozanib’s Long Half Tivozanib has High Tivozanib Significantly Life Creates a Unique PK Potency and Selectivity1 Reduces T-Regs Profile1 (Selectivity)

Pawlowski N et al. AACR 2013. Poster 3971. • and are not shown because absolute oral bioavailabilities are not reported in the literature. • The plots provide an overall assessment of differences between VEGFR-TKIs; the evaluation is substantially qualitative since threshold values cannot be assessed.

6 1. S. Fogli, et al., Cancer Treatment Reviews 84 (2020) 101966 TIVO-3 Pivotal Phase 3 Study TIVO-3: Study Design

Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to in Subjects With Refractory Advanced

Treatment Until N = 350 Progression*

• Histologically / cytologically Tivozanib Endpoints confirmed recurrent/metastatic RCC • Primary: PFS • ECOG PS 0 or 1 • Secondary: OS, • Failed at least two prior ORR, DoR, Safety regimens including VEGFR-TKI and Tolerability • Stratified by IMDC and prior regimen (TKI-TKI; TKI-CPI; TKI-Other) Randomize 1:1 Sorafenib • Life expectancy of 3 months Results published in or longer Lancet Oncology in December 2019

8 * Median duration for follow up was 19 months Met Primary Endpoint of Superior PFS

TIVO-3 Primary Endpoint: PFS of Tivozanib vs Sorafenib

44% Improvement in Median PFS

27% Risk Reduction Survival Probability Survival for Progression

Progression Free Survival Time or Death

Treatment Group Tivozanib Sorafenib

9 PFS final analysis, Oct 4, 2018 Secondary Endpoints: ORR & DoR Statistically Significant Improvement vs. Sorafenib

Tivozanib Sorafenib

ORR 18% 8% ORR p-value 0.02

Not reached 5.7 months Median DoR (12.9, NR) (5.6, NR)

100 Tivozanib (n=175) 80 Sorafenib (n=175) 60 40 20 0 -20 -40 -60 -80 -100 % Change in Target Lesion Longest Diameter Sum Diameter Longest Lesion inTarget Change %

10 ORR and DoR final analysis, Oct 4, 2018 Secondary Endpoint: Final Overall Survival

Tivozanib Sorafenib N=175 N=175 100 Median OS, months 16.39 19.15 (95% CI) (13.44–22.21) (14.95–24.21) HR 0.97 80 (95% CI) (0.75–1.25) p-value Stratified Log-rank 0.82

60

40

Tivozanib 20 Overall Survival (%) Survival Overall Sorafenib

0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 Months from Randomization

11

Final OS analysis, May 1, 2020 TIVO-3 OS HR Is Consistent With Marketed VEGFR TKIs That Compared to Another VEGFR TKI

Axitinib vs Sorafenib 1st line1 Cabozantinib vs 1st line2 All Randomized Patients

Axitinib vs Sorafenib 2nd Line3 vs Sunitinib 1st line4 In All Patients Median OS, months (95% CI) Pazopanib 28.3 months (95% CI 26.0–35.5) Sunitinib 29.1 months (25.4–33.1) HR 0·92, (95% CI 0.79–1.06); stratified log-rank p=0.24

Time (Months)

Note: Data from separate studies 12 1) Hutson et al. Clinical Genitourinary Cancer; Vol. 15, No. 1, 72-6. 2) Choueiri et al. European Journal of Cancer 2018; 94: 115e125 3) Motzer et. al. Lancet Oncol 2013; 14: 552–62. 4) Motzer, et al. N Engl J Med. 2014;370(18):1769-1770. IMDC Database: Third-line Treatment Demonstrated to Improve Survival ~2X vs. No Therapy*

**

**

13 *Wells JC, et al. Third-line in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol (2016) ** Internal Awareness Trial and Usage (ATU) Survey (May 2020) TIVO-3 Progression-Free Survival – Prior Checkpoint Inhibitor and TKI/TKI

100 Prior Checkpoint Inhibitor + VEGFR TKI

80 Tivozanib Sorafenib (n = 47) (n = 44) free - 60 Median PFS, months 7.3 5.1 (95% CI) (4.8, 11.1) (3.2, 7.4) 40 Tivozanib Survival (%) HR 0.55

Progression 20 (95% CI) (0.32, 0.94) Sorafenib P Value 0.028 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 ORR* 24.4% 6.8%

100 Two Prior VEGFR TKIs

80 Tivozanib Sorafenib (n = 79) (n = 80) free - 60 Median PFS, months 5.5 3.7 (95% CI) (3.6, 7.4) (3.6, 3.9) 40

Survival (%) HR 0.57

Progression 20 Tivozanib (95% CI) (0.39, 0.83) Sorafenib P Value 0.003 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 ORR* 15.2% 7.5%

Porta et al. ASCO 2019 14 Other + VEGFR TKI: (N=100) HR=0.98; 95% CI 0.62; 1.56, ASCO GI 2019 Tolerability: Dose Reductions, Interruptions and Discontinuations Due to AEs*

Tivozanib Sorafenib Characteristic (N=173)^ (N=170)^ Mean Number of Cycles Initiated 11.9 6.7

AEs Leading to Dose Reductions (%) 25 P=0.0147 39

AEs Leading to Dose Interruption (%) 50 P=0.0164 64

ADRs Leading to Permanent Discontinuation (%) 8 15

AE = Adverse Event, ADR = Adverse Drug Reaction 15 *Analysis as of Aug 15, 2019 ^Safety population Safety: Treatment-Related Adverse Events* (≥20% frequency in either arm)

Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term All Grades % Grade 3/4 % All Grades % Grade 3/4 % Treatment Related AEs 84 46 94 55 Hypertension 38 21 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 27 4 21 2 Dysphonia 24 1 8 0 Asthenia 22 5 17 4 PPE/HFSR** 16 1 39 10 Rash 5 0 24 8

>10% difference between arms

*Analysis as of Aug 15, 2019 16 **Palmar-plantar erythrodysesthesia (PPE), also known as hand-foot skin reaction (HFSR) ^Safety population Tivozanib Profile for Relapsed or Refractory RCC

• Robust data to guide treatment in highly refractory RCC are currently limited • No prospective, randomized data after SOC checkpoint inhibitor therapy • TIVO-3 provides first Phase 3 dataset in a 3rd and 4th line patient population • First large randomized study to prospectively evaluate treatment following a checkpoint inhibitor • Superior disease control (PFS, ORR & DoR) vs. active VEGFR TKI comparator, sorafenib • Superior tolerability compared to sorafenib • Fewer dose reductions, interruptions and discontinuations due to AEs • OS and safety profile consistent with the VEGFR TKI class • TIVO-3 OS HR consistent with other VEGFR TKI vs. VEGFR TKI pivotal studies in RCC • RCC monotherapy clinical trial safety data in >1,000 patients • Three years of EU post-marketing treatment experience

March 31, 2021 PDUFA Date

17 Tivozanib: Significant Potential Commercial Opportunity in Relapsed or Refractory RCC If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States

2nd Line Market (est. 2020) ~$700M1 1 >PFS with tivozanib may extend treatment duration

Extended OS from CPI may expand population eligible 3rd Line+ Market (est. 2020) 2 for 3rd line treatment ~$300M1  Expect opportunity to expand Efficacy + tolerability may increase patients  Potential to be first agent indicated 3 opting for 3rd and 4th line treatment for 3rd & 4th line 1st Line  Only pivotal dataset in RCC stratified 65%1 by prior checkpoint inhibitor 2nd Line 50%1 3rd Line

NA royalties to KHK are low- to mid-teens on net sales 25%1 4th Line

19 1 Decision Resources Pharmacor 2020 Market Projections July 2019 Launch Preparation Underway: RCC Market Addressable with Focused Oncology Team Concentration Curve of RCC treated patients • Experienced oncology sales 100% force for effective market coverage to be hired in 1Q 2021 90% (~60-70 FTEs) 80%

70% • Field payer team and comprehensive patient support 60% 80% of RCC Treated in place 50% Patients in 1,000

40% Accounts • Expanding MSL/Medical Affairs team

% Cumulative patients Cumulative % 30%

20% • Commercial infrastructure

10% comparable to cabozantinib 0 1,000 2,000 3,000 4,000 launch team Cumulative accounts

20 Source: SHS Claims Data for the time period May 2018 – April 2020 Physicians Support Potential Relevance of Tivozanib in R/R RCC

Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% I prefer using drugs that do not often require me to adjust or interrupt dose due to patient tolerability issues

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Efficacy Tolerability Likelihood to Prescribe Blinded Tivozanib Profile Ratings compared to current 50% treatment options in 40% refractory patients 30% 20% 80% 67% 10% 0% 1 2 3 4 5 6 7 Not at all likely Neutral Extremely Likely

21 Source: AVEO blinded Third-Party U.S. Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Checkpoint Inhibitor Combination Opportunities Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy Tolerability is Important in Combinations Tivozanib Significantly Reduces Tregs

Hammers, Emerging VEGF-I/O Combinations, ASCO 2017

23 Pawlowski N et al. AACR 2013. Poster 3971. Nakamura K et al. Cancer Res 2006;66:9134–9142. Phase 2 Data Presented at ESMO in September 2019

A Phase 1/2, Open-Label, Multi-Center Study of Tivozanib in Combination with (OPDIVO®) in Subjects with Advanced Renal Cell Carcinoma (TiNivo)

Tivozanib (1.0 mg/day) QD/21 days • N = 6 + nivolumab 240 mg Q2 weeks 1o safety, tolerability, and • ECOG PS ≤ 1 and life maximum tolerated dose expectancy ≥ 3 months 2o antineoplastic activity Phase 1 Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks

Full dose and schedule selected for Phase 2

• N = 22 • Tivozanib (1.5 mg/day) QD/21 days + Further evaluation of safety • ECOG PS ≤ 1 and life nivolumab 240mg Q2 weeks and antineoplastic activity expectancy ≥ 3 months Phase 2

24 TiNivo – Anti-tumor Activity Seen in Both Treatment Naive and Previously Treated RCC Patients

Treatment Naïve (12) Pre-Treated (13*) Overall (25) CR 8% - 4% PR 42% 62% 52% SD 42% 38% 40% PD 8% - 4% ORR (CR+PR) 50% 62% 56% DCR (CR+PR+SD) 92% 100% 96% 18.9 mo NR 18.9 mo mPFS (4.7, NR) (11.0, NR) (16.4, NR)

Second Line** *Includes 2 prior CPI Pts Tivozanib Mono1 Nivolumab Mono2 ORR 18% ORR 25% PFS 11.0 + PFS 4.6 **Data from separate studies 25 1 Molina et al. EJC 2018 2 Motzer et al. NEJM 2015 Barthelemy, et al. Tivozanib Combined With Nivolumab: Phase Ib/II Study in mRCC, ESMO 2019 Checkpoint Inhibitor Combinations in RCC: Promising Responses, All Phase 3 Currently 1st Line

50% Pre-treated 100% Pre-treated Treatment Naïve Treatment Naive Treatment Naive

Tivozanib Pembro Cabozantinib* + Axitinib Axitinib Efficacy 1 2 3 4 5 N (%) + Nivolumab + Lenvatinib Nivolumab + Pembro + Avel Phase 3 Total N=25 Total N=30 Total N=651 Total N=432 Total N=442 (ITT)

CR 1 (4) 0 (0) (8) (6) (3)

PR 13 (52) 20 (67) (47.7) (54) (48)

ORR 14 (56) 20 (67) (55.7) (60) (51)

PFS 18.9 mo 18.0 mo 16.6 mo 15.1 mo 13.8 mo

Dose Reductions 17% 73% 56.3% 20% 42%

Note: Data from separate studies *Dose of cabozantinib reduced to 40mg PO QD

1.Barthelemy, et al. Tivozanib Combined With Nivolumab: Phase Ib/II Study in mRCC, ESMO 2019; 2. Lee, et al. A Phase 1b/2 Trial of Lenvatinib + in Patients With Renal Cell Carcinoma, ASCO 2018; 3. Choueiri, T. et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 26 9ER trial, ESMO 2020; Presentation number 6960; 4. Powles, et al., Pembrolizumab plus axitinib vs Sunitinib as First Line Therapy in RCC: KEYNOTE 426, ASCO GU 2019; 5. Motzer, et al., plus axitinib vs. sunitinib for aRCC, NEJM, Volume 380, Issue 12. Immuno-Oncology Clinical Collaboration with AstraZeneca

Clinical Rationale: Combination of two agents has potential to show enhanced efficacy and tolerability profile among TKI/IO regimens.

Tivozanib Mono2 Mono3 No prior Tx / N=19 Prior Sorafenib / N=40 ORR 21% ORR 10.3% OS 7.5 + OS 13.2

HCC Revenue Projections - Major Markets (Millions USD)1 HCC Market – Key Opportunity1 $5,000

$4,000

$3,000

$2,000

$1,000 • Phase 2 enrolling • Costs shared equally and clinical drug $0 supplied by each company 2017 2027

Note: Clinical data from separate studies 1 Decision Resources HCC Disease Landscape and Forecast – Dec 2018 27 2 Lee S et al, ASCO GI 2018 3 Wainberg et al, ASCO 2017 Ficlatuzumab Anti-HGF/c-MET mAb Ficlatuzumab: A Potent anti-HGF/c-MET mAb

• Hepatocyte (HGF) pathway is frequently dysregulated in a broad range of human cancers • HGF can lead to both tumor growth and metastatic progression of cancer cells when dysregulated and is an escape mechanism to EGFR inhibitors • Ficlatuzumab has demonstrated differentiated inhibition of HGF • High affinity (pM) and slow off-rate for HGF • High potency (nM) inhibiting all biological activities of HGF, including autocrine/paracrine activation loops

Full global rights reacquired Aug 2020 Planned clinical manufacture enables potential Phase 3 registrational study in head & neck cancer

29 Ficlatuzumab + Combination: Strong Additive Anti-tumor Effect in Preclinical Models

• HNSCC is driven by multiple collaborating receptor tyrosine kinases – simultaneous inhibition of EGFR and c-Met/HGF pathways can result in increased treatment benefit • Indirect evidence that high c-Met may be a relevant predictive biomarker for ficlatuzumab activity in HNSCC

30 AVEO data on file Ficlatuzumab: Phase 2 Randomized Study Currently Enrolling Highly Refractory Patients

Randomized, open-label confirmatory Phase 2 study in combination with cetuximab, an EGFR-targeted antibody, in cetuximab-resistant, recurrent metastatic HNSCC

Treatment Until N = 60-70 Progression Ficlatuzumab • Recurrent and/or metastatic HNSCC (20mg/kg Endpoints q 2 weeks) • ECOG 0-1 • Primary: PFS • Clinical resistance to anti-EGFR • Secondary: OS, therapy, platinum and CPI ORR, DoR, Safety • Stratify Ficlatuzumab and Tolerability • P16 (HPV status) (20mg/kg q 2 weeks) + • Study center Randomize 1:1 Cetuximab (500 mg/m2 q 2 Final Results Expected weeks) Mid-2021

31 Ficlatuzumab: Potential for Long-Term Value Creation

Annual New Cases (US*) HNSCC: Randomized Phase 2 Trial Ongoing 70,000 (Ficlatuzumab + Erbitux vs. Ficlatuzumab) • Promising Phase 1 data - ASCO 2017 60,000 • Final Phase 2 data expected in mid-2021 50,000 AML: Randomized Phase 2 Trial on Hold Due to COVID-19 40,000 (Ficlatuzumab + Cytarabine vs. Ficlatuzumab) • Promising Phase 1/2 data - AACR 2019 30,000

20,000 Pancreatic Cancer: Phase 1/2 Trial

(Ficlatuzumab + Nab-paclitaxel + Gemcitabine) 10,000 • Topline data reported ASCO GI 2020 0 AML H&N mPC

32 *Source: NIH 2020 SEER Cancer Stats Pipeline and Near-Term Milestones Financial & Corporate

Potential cash runway into 2022*, including $88.8 million comprised of: • $68.8M in cash, cash equivalents, and marketable securities as of September 30, 2020 • $20M in debt financing available under Hercules debt facility contingent on FDA approval and specified 2021 sales Potential partnership milestones on the horizon • EUSA (ex-NA oncology partner) TIVO-3 data potential opt-in of $20M; European and Non-European reimbursement of $6M • Kyowa Kirin for KHK4951 (tivozanib reformulation) in wet-AMD: regulatory, development and commercial milestones up to $388M (remaining), royalty on any sales Accelerated commercial launch preparation • Commercial and medical affairs leadership in place. Recent field-focused additions: • Sales: VP of Sales; Regional Sales Directors; Director of Sales Training; Sales Operations Personnel • Market access: Director of Market Access; Director of Trade and Distribution; Director of Patient Access; Corporate Account Directors • Medical affairs: Regional MSLs • Tivozanib commercial launch supply on hand

*AVEO believes that its $68.8 million in cash, cash equivalents and marketable securities as of September 30, 2020, along with anticipated partnership cost sharing reimbursements, royalties from EUSA’s FOTIVDA sales and, if the pending marketing application for FOTIVDA is approved by the FDA, resulting product revenues upon commercial launch and the potential additional $20 million in credit under the Hercules loan, 34 which is available subject to milestone achievement, would allow the Company to fund planned operations into 2022. In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Accounting Standards Codification Subtopic 205-40), cash flows that are contingent on FDA approval, such as product revenues, cannot be reflected in the going concern assessment. As a result, Hercules loan funding contingent on such approval and such revenue is also excluded from the Company’s going concern assessment. Accordingly, the Company continues to have a going concern opinion. Key Potential Milestones

Tivozanib (VEGFR TKI) 2H 20 1H 21 2H 21

PDUFA Date (R/R RCC, March 31, 2021) Potential Commercial Launch HCC Phase 1/2 (Durvalumab + Tivo) Phase 1 Data (Ph2 ongoing)

Ficlatuzumab (HGF mAb) 2H 20 1H 21 2H 21 Reacquire Worldwide Rights  HNSCC Randomized (Ficlatuzumab +/- ERBITUX®) Ph2 POC Data

Pivotal Study Decision

AV-380 (GDF15 mAb) 2H 20 1H 21 2H 21 AV-380 IND Submission for Cancer Cachexia

CAN017 (AV-203) (ERBB3 mAb) 2H 20 2021 Initiate POC Study upon NRG1 Fusion Biomarker Evaluation

35 Corporate Overview

December 2020 Passionately pursuing a better life for patients with cancer